Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer
This is a parallel-track, randomized study will observe whether intravenous ascorbic acid reduces the reported fatigue in women receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer.
Fatigue
DRUG: Ascorbic Acid|OTHER: Normal Saline
Fatigue by self reported fatigue inventory questionnaire, Patients will complete the validated questionnaire Fatigue Symptom Inventory (FSI), Day 8 of each 4-week treatment cycle.
Fatigue ( EORTC QLQ-FA13), Patients will complete the validated questionnaire EORTC QLQ-FA13, Day 1 of each 4-week treatment cycle.|Fatigue ( EORTC QLQ-FA13), Patients will complete the validated questionnaire EORTC QLQ-FA13, Day 8 of each 4-week treatment cycle.|Fatigue ( EORTC QLQ-FA13), Patients will complete the validated questionnaire EORTC QLQ-FA13, Day 15 of each 4-week treatment cycle.|Fatigue by self reported fatigue inventory questionnaire, Patients will complete the validated questionnaire Fatigue Symptom Inventory (FSI), Day 1 of each 4-week treatment cycle.|Fatigue by self reported fatigue inventory questionnaire, Patients will complete the validated questionnaire Fatigue Symptom Inventory (FSI), Day 15 of each 4-week treatment cycle.
This is a parallel-track, randomized study will observe whether intravenous ascorbic acid reduces the reported fatigue in women receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer.